These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36516239)

  • 61. Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax.
    Candoni A; Lazzarotto D; Papayannidis C; Piccini M; Nadali G; Dargenio M; Riva M; Fracchiolla N; Mellillo L; Dragonetti G; Del Principe MI; Cattaneo C; Stulle M; Pasciolla C; De Marchi R; Delia M; Tisi MC; Bonuomo V; Sciumè M; Spadea A; Sartor C; Griguolo D; Buzzatti E; Basilico CM; Sarlo C; Piccioni AL; Cerqui E; Lessi F; Olivieri A; Fanin R; Luppi M; Pagano L
    Am J Hematol; 2023 Apr; 98(4):E80-E83. PubMed ID: 36651870
    [No Abstract]   [Full Text] [Related]  

  • 62. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
    Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
    Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
    [TBL] [Abstract][Full Text] [Related]  

  • 63. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
    Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
    Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
    Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
    Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience.
    Giudice V; Serio B; Ferrara I; Manzo P; Gorrese M; Pepe R; Bertolini A; D'Alto F; Verdesca F; Langella M; Filippelli A; Selleri C
    Front Pharmacol; 2022; 13():1052060. PubMed ID: 36618908
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 67. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Efficacy and safety of venetoclax combined with hypomethylating agents in the treatment of 83 patients with higher-risk myelodysplastic syndromes].
    Liu L; He F; Xu Y; Li T; Li YF; Tang P; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):277-283. PubMed ID: 38716600
    [No Abstract]   [Full Text] [Related]  

  • 69. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
    DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
    N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
    Waclawiczek A; Leppä AM; Renders S; Stumpf K; Reyneri C; Betz B; Janssen M; Shahswar R; Donato E; Karpova D; Thiel V; Unglaub JM; Grabowski S; Gryzik S; Vierbaum L; Schlenk RF; Röllig C; Hundemer M; Pabst C; Heuser M; Raffel S; Müller-Tidow C; Sauer T; Trumpp A
    Cancer Discov; 2023 Jun; 13(6):1408-1427. PubMed ID: 36892565
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
    Soboń A; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Popławska L; Morawska M; Tryc-Szponder J; Bołkun Ł; Rybka J; Pruszczyk K; Juda A; Majeranowski A; Iskierka-Jażdżewska E; Steckiewicz P; Wdowiak K; Budziszewska B; Jamroziak K; Hus I; Lech-Marańda E; Puła B
    Ann Hematol; 2023 Aug; 102(8):2119-2126. PubMed ID: 37392368
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
    Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia.
    Chen TT; Lin CC; Lo WJ; Hsieh CY; Lein MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539418
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
    Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
    Karrar O; Abdelmagid M; Rana M; Iftikhar M; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Elliott MA; Mangaonkar A; Saliba A; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):E63-E66. PubMed ID: 38100217
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
    Rausch CR; DiNardo CD; Maiti A; Jammal NJ; Kadia TM; Marx KR; Borthakur G; Savoy JM; Pemmaraju N; DiPippo AJ; Daver NG; Chew SM; Sasaki K; Issa GC; Short NJ; Takahashi K; Ohanian MN; Ning J; Xiao L; Alvarado Y; Kontoyiannis DP; Ravandi F; Kantarjian HM; Konopleva MY
    Cancer; 2021 Jul; 127(14):2489-2499. PubMed ID: 33793970
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia.
    Aiba M; Shigematsu A; Suzuki T; Miyagishima T
    Ann Hematol; 2023 Mar; 102(3):541-546. PubMed ID: 36646889
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
    Canaani J; Frisch A; Pollyea DA; Schwartz M; Aumann S; Ganzel C; Haran A; Even-Zohar NG; Shaulov A; Vainstein V; Moshe Y; Ofran Y; Wolach O; Nachmias B
    Eur J Haematol; 2023 Sep; 111(3):365-372. PubMed ID: 37254665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.